ClinicalTrials.gg

Program

sotorasib

Also written as “Sotorasib”, “AMG 510” and “avutometinib and sotorasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Noonan Syndrome, led by 5 companies.

Furthest: phase 3, since Mar 5, 202028 company-led studies, 6 open or runningNext primary completion: Dec 17, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen244 open or runningphase 3since Mar 5, 2020Jun 26, 2018Dec 17, 2026phase 1 · NCT04185883
Criterium10 open or runningphase 2since Dec 6, 2021Dec 6, 2021none ahead
Effector Therapeutics11 open or runningphase 2since Sep 10, 2019Sep 10, 2019none ahead
Erasca10 open or runningphase 1since Jul 2, 2021Jul 2, 2021none ahead
Verastem11 open or runningphase 2since Sep 29, 2021Sep 29, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Jun 26, 2018.

  1. Jun 14, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungAmgen · NCT04933695 · 42 enrolled · United States, Belgium, Denmark and more
  2. Jul 2, 2021Erasca's first study: phase 1 study in Noonan SyndromeNew to ErascaErasca · NCT04959981 · 24 enrolled · United States
  3. Sep 7, 20212 phase 1 studies in Healthy ParticipantsAmgen · NCT05045638, NCT05048784
  4. Sep 29, 2021Verastem's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to VerastemVerastem · NCT05074810 · 153 enrolled · United States, Belgium, France and more
  5. Dec 6, 2021Criterium's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to CriteriumCriterium · NCT05180422 · United States
  6. Jan 6, 2022Phase 3 study in Colorectal NeoplasmsAmgen · NCT05198934 · 160 enrolled · United States, Australia, France and more
  7. Apr 7, 2022Phase 1 study in Healthy ParticipantsAmgen · NCT05327491 · 146 enrolled · United States
  8. Aug 3, 2022Phase 1 study in Healthy VolunteersAmgen · NCT05497557 · 16 enrolled · United States
  9. Sep 19, 2022Phase 1 study in Healthy VolunteersAmgen · NCT05550129 · 13 enrolled · United States
  10. Oct 3, 20228 phase 1 studiesAmgen · NCT05568082, NCT05571163, NCT05577624 and 5 more
  11. May 23, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT05920356 · 750 planned · United States, Argentina, Australia and more
  12. Sep 25, 2023Phase 1 study in Healthy ParticipantsAmgen · NCT06061523
  13. Jan 15, 2024Phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649 · 450 planned · United States, Argentina, Australia and more
  14. Sep 8, 2025Phase 2 study in Advanced Solid TumorsAmgen · NCT07172919 · 14 planned · United States, Australia, France and more

Ahead

  1. Dec 17, 2026Primary completion: phase 1 study in Advanced Solid TumorsAmgen · NCT04185883
  2. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT05920356
  3. Jul 1, 2028Primary completion: phase 2 study in Advanced Solid TumorsAmgen · NCT07172919
  4. Sep 25, 2028Primary completion: phase 3 study in Colorectal NeoplasmsAmgen · NCT06252649

TargetBeta

KRAS →read by rule
“An orally available inhibitor of the specific KRAS mutation, p.G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 28 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07172919Advanced Solid Tumors · United States, Australia, France and more2RecruitingAmgenJul 1, 202814
NCT06252649Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingAmgenSep 25, 2028450
NCT06061523Healthy Participants1WithdrawnAmgenSep 9, 20240
NCT05920356Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingAmgenJun 30, 2027750
NCT05599828Healthy Participants · United States1CompletedAmgenSep 13, 202014
NCT05598281Healthy Participants · United States1CompletedAmgenNov 19, 201914
NCT05581992Healthy Participants · United States1CompletedAmgenJan 26, 202014
NCT05581758Healthy Participants · United States1CompletedAmgenNov 25, 201914
NCT05578859Healthy Subjects · United States1CompletedAmgenMar 24, 20208
NCT05577624Healthy Participants · United States1CompletedAmgenDec 1, 201914
NCT05571163Healthy Participants · United States1CompletedAmgenJun 14, 202013
NCT05568082Healthy Participants · United States1CompletedAmgenDec 17, 201914
NCT05550129Healthy Volunteers · United States1CompletedAmgenNov 25, 201913
NCT05497557Healthy Volunteers · United States1CompletedAmgenSep 8, 202216
NCT05327491Healthy Participants · United States1CompletedAmgenJul 17, 2022146
NCT05198934Colorectal Neoplasms · United States, Australia, France and more3CompletedAmgenJul 16, 2025160
NCT05180422Carcinoma, Non-Small-Cell Lung · United States2WithdrawnCriteriumJan 31, 20230
NCT05074810Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more2Active, not recruitingVerastemJun 2026153
NCT05048784Healthy Participants · United States1CompletedAmgenFeb 18, 2022145
NCT05045638Healthy Participants · United States1CompletedAmgenOct 10, 202113
NCT04959981Noonan Syndrome · United States1CompletedErascaApr 27, 202324
NCT04933695Carcinoma, Non-Small-Cell Lung · United States, Belgium, Denmark and more2TerminatedAmgenMay 28, 202542
NCT04887064Hepatic Impairment · United States1CompletedAmgenMar 9, 202220
NCT04380753Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation · Hong Kong, Taiwan1CompletedAmgenDec 31, 202112
NCT04303780KRAS p, G12c Mutated /Advanced Metastatic NSCLC · United States, Australia, Belgium and more3CompletedAmgenAug 2, 2022345
NCT04185883Advanced Solid Tumors · United States, Australia, Austria and more1Active, not recruitingAmgenDec 17, 2026610
NCT04092673Solid Tumor, Adult · United States2RecruitingEffector TherapeuticsDec 31, 202430
NCT03600883KRAS p.G12C Mutant Advanced Solid Tumors · United States, Australia, Austria and more2CompletedAmgenMay 29, 2026713

How it is read

Names in the registry

  • “Sotorasib”, 14 entries
  • “AMG 510”, 12 entries
  • “sotorasib”, 1 entry
  • “avutometinib and sotorasib”, 1 entry
  • “avutometinib and sotorasib and defactinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.